Dynamics and epigenetic signature of regulatory T-cells following antiretroviral therapy initiation in acute HIV infection

Alexis Yero¹, Tao Shi¹, Omar Farnos¹, Jean-Pierre Routy²,3, Cécile Tremblay⁴,5, Madeleine Durand⁴, Christos Tsoukas²,6, Cecilia T. Costiniuk⁴,5, Mohammad-Ali Jenabian¹,5,7,*

¹ Department of Biological Sciences and CERMO-FC Research Centre, Université du Québec à Montréal (UQAM), Montreal, QC, Canada
² Research Institute of McGill University Health Centre, Montreal, QC, Canada
³ Chronic Viral Illness Service, Division of Infectious Disease, Department of Medicine, Glen Site, McGill University Health Centre, Montreal, QC, Canada
⁴ CHUM Research Centre, Montreal, QC, Canada
⁵ Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
⁶ Division of Clinical Immunology and Allergy, Faculty of Medicine, McGill University, Montreal, QC, Canada
⁷ Department of Microbiology & Immunology, McGill University, Montreal, QC, Canada

Abstract

Background: HIV infection promotes the expansion of immunosuppressive regulatory T-cells (Tregs), contributing to immune dysfunction, tissue fibrosis and disease progression. Early antiretroviral treatment (ART) upon HIV infection improves CD4 count and decreases immune activation. However, Treg dynamics and their epigenetic regulation following early ART initiation remain understudied.

Methods: Treg subsets were characterized by flow cytometry in 103 individuals, including untreated HIV-infected participants in acute and chronic phases, ART-treated in early infection, elite controllers (ECs), immunological controllers (ICs), and HIV-uninfected controls. The methylation status of six regulatory regions of the foxp3 gene was assessed using MiSeq technology.

Findings: Total Treg frequency increased overtime during HIV infection, which was normalized in early ART recipients. Tregs in untreated individuals expressed higher levels of activation and immunosuppressive markers (CD39, and LAP(TGF-β1)), which remained unchanged following early ART. Expression of gut migration markers (CCR9, Integrin-β7) by Tregs was elevated during untreated HIV infection, while they declined with the duration of ART but not upon early ART initiation. Notably, gut-homing Tregs expressing LAP(TGF-β1) and CD39 remained higher despite early treatment. Additionally, the increase in LAP(TGF-β1) Tregs overtime were consistent with higher demethylation of conserved non-coding sequence (CNS)-1 in the foxp3 gene. Remarkably, LAP(TGF-β1)-expressing Tregs in ECs were significantly higher than in infected subjects, while the markers of Treg activation and gut migration were not different.

Interpretation: Early ART initiation was unable to control the levels of immunosuppressive Treg subsets and their gut migration potential, which could ultimately contribute to gut tissue fibrosis and HIV disease progression.

Funding: This study was funded by the Canadian Institutes of Health Research (CIHR, grant MOP 142294) and in part by the AIDS and Infectious Diseases Network of the Réseau SIDA et maladies infectieuses du Fonds de recherche du Quebec-Sante (FRQ-S).

© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
**Research in Context**

**Evidence before this study**

Early HIV infection is characterized by rapid CD4 T-cell depletion, a dramatic increase in immune activation, and irreversible gut mucosal fibrosis, which are associated with increased frequencies of immunosuppressive regulatory T-cells (Tregs). Tregs contribute to HIV disease progression by promoting immune dysfunction and tissue fibrosis. Antiretroviral therapy (ART) initiation as early as possible is recommended to decrease HIV burden, immune dysfunction, and secondary HIV transmission. However, ART is unable to restore gut mucosal integrity, and such mucosal damage is present even in individuals that naturally control HIV viral replication, known as elite controllers (ECs). The impact of early ART initiation during acute HIV infection on Tregs subset dynamics remains understudied.

**Added value of this study**

Herein, we assessed the dynamics of various Treg subsets in HIV-infected individuals with different clinical outcomes and after early ART initiation. We found that, despite decreasing total Tregs frequencies, early ART initiation was unable to normalize the proportion of immunosuppressive Treg subsets, including CD39⁺, and LAP(TGF-β1)⁺ Tregs, and their potential to migrate toward the gut. Importantly, we showed that even in ECs, the frequencies of pro-fibrotic Tregs (LAP(TGF-β1)⁺) Tregs and their migration into the gut were higher than in uninfected individuals, which support previous reports on gut fibrosis in ECs. Additionally, for the first time, we evaluated the epigenetic regulation of six major regions of the foxp3 gene, the master regulator of Treg suppressive functions. We found increased demethylation of conserved non-coding sequences (CNS) 1 in the foxp3 gene, which is known to be induced by TGF-β1.

**Implications of all the available evidence**

Our findings fill a knowledge gap on progressive and irreversible gut fibrosis mechanisms despite early ART initiation. Our results highlight the role of pro-fibrogenic Tregs via CD39/TGF-β1 pathway and their homing in the gut despite early ART. These observations underscore Tregs as potential targets for HIV immunotherapeutic interventions in combination with ART.

demonstrate higher demethylation in the foxp3 promoter compared to those of healthy controls, indicating an enhanced function [12]. Additionally, Foxp3 downregulation in HIV-infected Tregs was associated with lower demethylation in the foxp3 locus [13].

Several Treg subsets with high immunosuppressive functions have been identified, including cytotoxic T lymphocyte antigen 4 (CTLA4)⁺ Tregs, programmed cell death protein 1 (PD1)⁺ Tregs, CD39⁺ Tregs, and TGF-β1⁺ Tregs. It has been shown that CTLA4 impedes CD28 co-stimulation by competitive binding to CD80/CD86 [1,14], and Treg-specific CTLA4 deficiency impairs Treg suppressive function [15]. CTLA4⁺ Tregs increase during HIV infection [9,16,17] and remains higher despite antiretroviral therapy (ART) [18]. PD1 is expressed on Tregs under resting and activated conditions [19,20] and prevents the proliferation and immune responses of effector T-cells [21,22]. Untreated HIV infection increases PD1⁺ Tregs, and their levels positively correlate with viral load and exhaustion of total CD4 and CD8 T-cells [23]. The ectonucleotidase CD39 hydrolyzes inflammatory ATP into ADP and AMP, followed by immunosuppressive adenosine production by another ectonucleotidase, CD73 [22,24,25]. Our team and others reported that CD39⁺ Tregs and adenosine pathways are involved in suboptimal anti-HIV immune responses and disease progression, and their levels remain higher than uninfected individuals even under suppressive ART [26-28].

Another major contribution of Tregs in HIV disease progression, which starts early after HIV infection, is via TGF-β1 production, which promotes collagen-1 deposition and lymphoid tissue fibrosis [29,30]. TGF-β1 inhibits effector T-cell proliferation, suppresses the effector functions of CD8 T-cells, and promotes the differentiation of pTregs [31-33]. Tissue fibrosis is an irreversible phenomenon that obstructs cell-cell interactions and limits trafficking and homing of CD4 T-cells and IL-7 bioavailability, causing persistent immune dysregulation [29,30,34-37]. Furthermore, gut mucosal fibrosis contributes to gut dysbiosis and progressive microbial translocation from the gut to the periphery, which promotes systemic chronic inflammation and accelerated comorbidities and non-AIDS malignancies [38,39]. Notably, gut mucosal fibrosis occurs even in HIV elite controllers (EC) while they exhibit similar peripheral Treg levels compared to healthy individuals [40,41].

The acute phase of HIV infection is characterized by a rapid CD4 T-cell depletion and increased immune activation and dysfunction, mainly in the major sites of HIV replication and fibrosis, such as the gut-associated lymphoid tissues (GALT) [23,42-45]. Currently, it is highly recommended to initiate ART as early as possible upon HIV exposure since it improves CD4 T-cell count recovery and anti-HIV effector immune responses, while early ART decreases immune activation and viral reservoir size [43,46]. Long-term ART has been shown to decrease Treg frequency in the blood at levels similar to those of uninfected individuals [10,47]. Nevertheless, even early ART initiation was unable to completely reverse HIV-induced damage in GALT [41,48]. However, to date, the dynamics of Treg subsets and the epigenetics status of foxp3 gene during acute HIV infection and the impact of early ART initiation remains understudied. In this study, in HIV-infected individuals with different clinical outcomes, we evaluated the dynamics of Tregs and methylation signature of foxp3 gene overtime during HIV infection and following early ART initiation in the acute phase. We found that early ART initiation failed to control the expansion of immunosuppressive Treg subsets and their potential migration to the gut, which might contribute to immune dysfunction and tissue fibrosis in the GALT.

2. Methods

2.1. Study population

Frozen peripheral blood mononuclear cells (PBMCs) from HIV-infected and uninfected controls were obtained from the Canadian
Cohort of HIV Infected Slow Progressors, Montreal Primary HIV Infection cohort, and McGill University Health Centre. Among study participants, 26 had acute HIV infection, defined as being within <180 days (median [IQR] 90 [43-126] days) from the estimated date of HIV infection. Chronically infected patients were either untreated (n=10) with more than one year of infection or ART-treated (n=11). HIV ECs (n=18) with undetectable plasma viral load (VL) in the absence of ART, untreated immunological controllers (ICs, n=18) with VL<5000 copies/ml and CD4 > 400 cells/mm³, as well as 20 HIV-uninfected controls were also included. Additionally, we prospectively assessed 20 acutely infected individuals, of whom ten had initiated ART during the acute infection, while the remaining ten patients were untreated. Follow-up specimens from the longitudinal cohorts were not included in our cross-sectional analysis.

2.2. Ethical considerations
This study was conducted according to the Declaration of Helsinki and received approval from the Ethical Review Board (#2014-452) of the Université du Québec à Montréal (UQAM). All study subjects provided written informed consent prior to their blood collection.

2.3. Flow cytometry analysis
Multiparameter flow cytometry was performed on thawed PBMCs. Optimal concentrations of fluorochrome-conjugated antibodies were used for immunological staining as detailed in Supplementary Table 1. Dead cells were excluded for the analysis using the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Oregon, USA). Following extracellular staining, intracellular staining of FoxP3, CTLA4, and Helios was performed after permeabilization with the Transcription Factor Buffer Set (BD Bioscience, New Jersey, USA). Data acquisition was performed on a BD LSR Fortessa X-20 cytometer, and results were analysed by FlowJo V10.7.1 (Oregon, USA).

2.4. Bisulfite DNA conversion and Nested-Polymerase chain reaction
FoxP3+ CD4 T-cells were FACS-sorted using a FACS Aria III sorter (BD Biosciences) following the gating strategy presented in Supplementary Fig. 1. Of note, to evaluate the epigenetic status of the foxp3 gene, only male donors were used to avoid random X chromosome inactivation in females [49]. Genomic DNA from sorted FoxP3+ CD4 T-cells was isolated using the DNeasy kit (Qiagen, Hilden, Germany). Bisulfite conversion of DNA samples was conducted using the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). Six specific CpG-rich regions [50], including enhancer, proximal promoter, and CNS0-CNS3, were amplified by PCR using primers targeting specifically bisulfite converted DNA, none of which binds to areas containing CpG sites to avoid potential bias (Supplementary Table 2). Briefly, PCRs were carried out in 25 μl reaction volumes containing a final concentration of 1X PCR buffer (Platinum Taq DNA polymerase, Invitrogen), 1.5 mM MgCl2, 0.2 mM of dNTP mix, 0.4 μM forward and reverse primers, and 2-4 μl of bisulfite DNA template (external PCR) or external PCR product (internal PCR). The thermocycling program used was as follows: 95°C for 2 min, followed by 40 cycles of 95° C for 30 s, 40 s, 72°C for 1 min, and a final extension step of 72°C for 10 min. The optimized 1μl for each region was as follows: 50°C for proximal promoter, 58.1°C for enhancer, 51.8°C for CNS0 and CNS3, 52.7°C for CNS1, and 59.1°C for CNS2. Following amplification, the quality of PCR products was assessed on a 2% agarose gel.

2.5. Next-generation sequencing
PCR products were purified using just-a-plate 96 PCR purification and normalization kit (Charm Biotech, MA, USA). The libraries were then generated by pooling 5 μl of each sample, and the cleanup steps were performed using AMPure XP Beads (Beckman Coulter, California, USA). Purified libraries were quantified using the Qubit dsDNA HS assay (Life Technologies, California, USA) and the NEBNext Library Quant Kit for Illumina (New England Biolabs, MA, USA). The average size fragment was determined using a high sensitivity DNA assay on the 2100 Bioanalyzer System (Agilent, California, USA). Finally, the amplicon pool was spiked with 12% of PhiX control (loaded at a final concentration of 6 pM), and sequencing was performed using the MiSeq® Reagent Kit v3 cartridge 600 cycles (PE300) (Illumina). Library preparation and sequencing were carried out at the Genomics Core of the CERMO-FC research center, UQAM.

2.6. Bioinformatic analysis
Bisulfite treated sequences within FASTQ files were trimmed for adapters and bases of quality lower than 30 at the 3’ extremities using Trimgalore version 0.4.5. Trimmed reads were then mapped on chromosome X of the human genome GRCh37 using Bismark version 0.19.0. Default parameters were used for the alignment, which was performed with Bowtie 2.1.0. Bioinformatic analysis was done by the Bioinformatics Core Facility at the Institute for Research in Immunology and Cancer, Université de Montréal.

2.7. Statistical analysis
Statistical analysis was performed using GraphPad Prism V6.01 (California, USA). Results are presented throughout the text as median with interquartile range (IQR). The distribution of variables was initially determined by the Kolmogorov–Smirnov test. Then, the Kruskal–Wallis test was performed to determine whether significant differences exist between the six study groups. Nonparametric Mann-Whitney and Wilcoxon rank tests were used for unpaired and paired variables, respectively. The Spearman correlation coefficient test established the correlation between variables. Only statistical significances (p<0.05) are presented in the figures (*, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001).

2.8. Role of funding source
Funders had no role in study design, data collection, data analyses, interpretation, or writing of report.

3. Results
3.1. Characteristics of the study populations
Chronically infected individuals on ART in the cross-sectional study versus chronically infected individuals on ART in the longitudinal study were significantly older (median age: 51 versus 36.5 years, Mann-Whitney p=0.04) with longer duration of HIV infection (median: 12.7 versus 2.27 years, p=0.0001) and on longer duration on ART (median: 14.58 versus 1.72 years, Mann-Whitney p=0.0002). ART initiation in these individuals was also more delayed (median years of ART initiation post-infection of 1.11 versus 0.46 years, Mann-Whitney p=0.05) (Tables 1, 2). We thus assessed the impact of early ART on our study measures based on the longitudinal analysis. In chronic infection, ART normalized the CD4 T-cell count, yet the CD8 T-cell count remained elevated compared to uninfected individuals. Consequently, despite improved CD4/CD8 ratio, early ART was unable to normalize this parameter in treated individuals. EC and IC exhibit CD4 T-cell counts similar to uninfected individuals, despite higher...
CD8 T-cell counts. Besides, individuals with chronic infection on long-term ART and ECs groups were the oldest study group with the longest duration of HIV infection. In longitudinal specimens, after early ART initiation, the CD4 T-cell count and CD4/CD8 ratio were improved significantly (Wilcoxon p = 0.04 and p = 0.002, respectively). Of note, no significant difference was detected between clinical characteristics of two n = 10 acute individuals in untreated and treated longitudinal sub-groups (Table 2). All ART-treated individuals had a plasma VL below the level of detection. The clinical characteristics of study participants are described in Tables 1 and 2.

3.2. Early ART initiation decreased but did not normalize T-cell immune activation and senescence

As expected, untreated HIV infection was associated with increased CD38^+HLADR^+ activated CD4 and CD8 T-cells (Fig. 1a, d, e).

Table 1
Clinical characteristics of study groups.

| Characteristics                        | Non-infected (n=20) | Acute (n=26) | Chronic ART- (n=10) | Chronic ART+ (n=11) | EC (n=18) | IC (n=18) | p-values |
|-----------------------------------------|---------------------|--------------|---------------------|---------------------|-----------|-----------|----------|
| Male sex, n (%)                         | 15^a (75%)          | 26^h,i       | 10^k,l              | 11^m,n              | 10^k,m,n  | 10^l,ln   | p < 0.0001|
| Age, years [median (IQR)]              | 39^d (35.70-47)    | 39.5^e       | 32.5^f,g             | 51^l,k              | 55^l,k    | 35^l       | p = 0.0005|
| Nadir CD4+ cell count, cells/μl [median (IQR)] | NA                 | 330^f       | 310^f                | 334                 | 551.5     | 495^g,i    | p = 0.07   |
| CD4+ T-cell count, cells/μl [median (IQR)] | 632^b              | 460^h,i      | 440^h,i              | 603                 | 730^h,i   | 680^j      | p = 0.0002 |
| CD8+ T-cell count, cells/μl [median (IQR)] | (640-1630)         | 750^i        | 629-1133             | 743                 | 730^i     | 800^j      | p = 0.0003 |
| CD4+/CD8+ T-cell count ratio [median (IQR)] | 2.84^k,l,d,e       | 0.46^k,li    | 0.48^k,li            | 0.87^k,l            | 0.95^k,li | 0.81^ki,ln | p < 0.0001|
| Viral load, log_{10} copies/mL [median (IQR)] | NA                 | 4.39^b,e     | 4.56^b,e             | 1.60^j,k            | 1.85^b,m  | 2.91^j,i,o | p < 0.0001|
| Duration of infection, years [median (IQR)] | NA                 | 0.25^d,k,i   | 0.25^d,k,i           | 12.40^j,i           | 15.3^b,k   | 7.55^b,i   | p < 0.0001|
| Time of ART initiation years post-infection [median (IQR)] | NA                 | NA          | NA                  | 1.11                | NA        | NA        | NA       |
| Duration of ART, years [median (IQR)]   | NA                 | NA          | NA                  | 14.58               | NA        | NA        | NA       |

Results are shown as median and interquartile range (IQR). NA: not applicable, EC: Elite controllers, IC: Immunological controllers p-values come from comparing the six groups using the Kruskal-Wallis test. Significant differences (p < 0.05) following Mann-Whitney U test or Fisher’s test are mentioned as follow: a: Non-infected vs Acute, b: Non-infected vs Chronic (ART-), c: Non infected vs Chronic (ART+), d: Non-infected vs EC, e: Non-infected vs IC, f: Acute vs Chronic (ART-), g: Acute vs Chronic (ART+), h: Acute vs EC, i: Acute vs IC, j: Chronic (ART-) vs Chronic (ART+), k: Chronic (ART-) vs EC, l: Chronic (ART-) vs IC, m: Chronic (ART+) vs EC, n: Chronic (ART+) vs IC, o: EC vs IC.

Table 2
Clinical characteristics of longitudinal samples.

| Characteristics                        | Untreated | ART-Treated |
|-----------------------------------------|-----------|-------------|
| Male sex, n (%)                         | 10 (100%) | 10 (100%)   |
| Age, years [median (IQR)]              | 39.5 (35.50-43.25) | 39.5 (34.75-43) |
| Nadir CD4+ cell count, cells/μl [median range(IQR)] | 365 | NA |
| CD4+ T-cell count, cells/μl [median (IQR)] | 515 | 595 |
| CD8+ T-cell count, cells/μl [median (IQR)] | 830 | 953 |
| CD4+/CD8+ T-cell count ratio [median (IQR)] | 0.50^a | 0.50^a |
| Viral load, log_{10} copies/mL [median (IQR)] | 4.07^a | 4.60^a |
| Duration of infection, years [median (IQR)] | 0.22^a | 2.19^a |
| Time of ART initiation years post-infection, years [median (IQR)] | NA | NA |
| Duration of ART, years [median (IQR)]   | NA | NA |

Results are shown as median and interquartile range (IQR). NA: not applicable. Significant differences (p < 0.05) following Wilcoxon signed-rank test are mentioned as follow: a: Acute vs Chronic (ART-), b: Acute vs Chronic (ART+).
Early ART initiation reduced CD8 T-cell immune activation (Wilcoxon p=0.002), while their levels remained higher than those of HIV-uninfected controls (Mann-Whitney p < 0.0001; Fig 1d, e). HIV infection increased the frequencies of both senescent (CD28-CD57+) and exhausted (PD1+CD57+) CD8 T-cells in all study groups (Fig. 1b, g, i), while early ART initiation failed to mitigate this increase (Mann-
Whitney p < 0.0004 and p < 0.0001, respectively). HIV infection also increased levels of CD4 T-cell exhaustion, which was reduced but not normalized by early ART (Mann-Whitney p = 0.009; Fig. 1c, h), while no difference in senescent CD4 T-cells was observed among study groups (Fig. 1b, f). Both CD4 and CD8 T-cell immune activation and senescence correlated negatively with CD4/CD8 ratios and positively with VL (Supplementary Fig. 2). Interestingly, significant decreases in CD4 and CD8 immune activation, and CD8 exhaustion, were correlated with the duration of ART (Table 3). EC and IC groups presented significantly lower CD4 and CD8 immune activation than untreated HIV-infected individuals, while their CD8 immune activation, senescence, and exhaustion remained higher than uninfected controls (Fig. 1).

3.3. Early ART initiation suppressed the expansion of total Tregs

Chronic HIV infection was associated with an increase in total Treg (CD4+CD25highCD127lowFoxP3+) frequencies compared to uninfected individuals (Mann-Whitney p < 0.01 in both cross-sectional and longitudinal analysis), which was suppressed following early ART initiation (Fig 2a, b). The frequency of total Tregs was inversely correlated with CD4/CD8 ratio and positively with CD4 immune activation (Supplementary Fig. 3). Treg frequencies in ECs and ICs were lower than chronically untreated HIV+ individuals (Mann-Whitney p < 0.05 for both comparisons) and similar to uninfected individuals (Fig 2b). We also found heterogeneity in Treg differentiation in HIV-infected individuals compared to uninfected controls (Fig. 2a, c-f). Indeed, acute HIV infection was associated with an increase in the frequencies of naïve Tregs (Mann-Whitney p = 0.001), along with a decrease in central memory (CM, Mann-Whitney p = 0.003) and effector memory (EM, Mann-Whitney p = 0.0001) Tregs (Fig. 2c-e). In longitudinal analysis, early ART initiation didn’t affect these subsets. However, longer duration of ART was associated with significant increases CM and EM Tregs (Spearman p = 0.007 and p = 0.02, respectively) and with a decline in naïve and TD Tregs (Spearman p < 0.0001 and p = 0.03, respectively; Table 3). Interestingly, the EC group had similar frequencies of naïve, CM and EM and lower terminally differentiated (TD) Tregs compared to uninfected individuals (Fig 2c, f). These results collectively showed that early ART initiation controlled the expansion of Tregs and affected the distribution of their memory subsets.

3.4. Early ART initiation failed to normalize Treg subsets known for their highly immunosuppressive capacity

As mentioned before, various Tregs subsets, including CTLA4+ [9,16,17], PD1+ [23], CD39+ [26-28], and TGF-β1+ [29] Tregs increase during untreated HIV infection and impact negatively in the outcome of the disease. Herein, we observed an increase in the frequencies of CTLA4+ Tregs, PD1+ Tregs, and CTLA4+PD1+ Tregs (Mann-Whitney p = 0.005, p = 0.0001 and p = 0.0001, respectively) during acute HIV infection compared to uninfected individuals, which were not restored longitudinally after early ART initiation (Fig. 3a, d-f). Meanwhile, longer duration of ART was associated with a decline in PD1-expressing Tregs (Spearman p = 0.02; Fig 3c, f; Table 3). ECs and ICs showed lower CTLA4+ Tregs, PD1+ Tregs, and CTLA4+PD1+ Treg frequencies than acute HIV-infected groups while similar CTLA4+ Tregs and CTLA4+PD1+ Treg than uninfected controls (Fig. 3d-f). A new subset of memory CD4 T-cells that share Treg characteristics described as memory CTLA4+PD1+ FoxP3+ has been recently proposed as viral reservoirs within peripheral lymph nodes of ART-treated SIV-infected rhesus macaques [51]. In this regard, we found that acute HIV infection increased the frequencies of these cells compared to uninfected individuals (p = 0.04), while early ART could not restore their frequencies, suggesting a potential contribution of Tregs in viral persistence despite early ART (Fig. 3b, g).

Higher CD39+ Tregs were observed in acute HIV-infected and ART-treated individuals compared to uninfected controls (Mann-Whitney p = 0.02 and p = 0.0001, respectively), and ART duration didn’t affect CD39+ Tregs frequencies (Fig. 3c, i; Table 3). In concordance with a previous report [16], EC had similar CD39+ Treg frequencies than uninfected controls (Fig. 3h). TGF-β1 is initially synthesized as a pro-TGF-β1, which is further cleaved to produce the dimeric propeptides called a latency-associated peptide (LAP) that associates non-covalently with mature TGF-β to prevent TGF-β1 binding to its receptor and subsequent activity [52]. LAP(TGF-β1)+ Tregs and CD39LAP(TGF-β1)+ Tregs populations (Fig. 3c, i, j) were increased during HIV infection versus uninfected individuals (Mann-Whitney p < 0.0001 for both comparison) and were not reduced upon early ART initiation. Interestingly, the frequencies of LAP(TGF-β1)+ Tregs correlated negatively with duration of ART (Spearman p = 0.04; Table 3) and CD4/CD8 ratio (Spearman p = 0.002) and positively with immune activation (Spearman p = 0.04 for CD4 and p = 0.01 for CD8 activation; Supplementary Fig. 4). In addition, the frequencies of LAP(TGF-β1)+ Tregs remained elevated in EC group compared to uninfected controls (Mann-Whitney p = 0.01). Overall, our data demonstrated that early ART initiation was unable to normalize the frequencies of immunosuppressive Treg subsets, nor did it affect the frequencies of a Treg population previously described as a viral reservoir (Memory CTLA4+PD1+ FoxP3+ T-cells).

Table 3

Correlation between clinical and immunological parameters and duration of ART (years).

| Immunological measure       | Correlations with duration of ART (years) |
|-----------------------------|------------------------------------------|
|                             | r  | p-value |
| CD4 T-cells count           | 0.1030 | 0.7     |
| CD8 T-cells count           | 0.0088 | 0.9     |
| CD4/CD8 ratio               | 0.0558 | 0.8     |
| CD4 Activation              | -0.5643 | 0.02    |
| CD4 Immunosenesence         | -0.2735 | 0.3     |
| CD4 exhaustion              | -0.3076 | 0.2     |
| CD8 activation              | 0.0617 | 0.01    |
| CD8 Immunosenesence         | -0.2176 | 0.4     |
| CD8 exhaustion              | 0.0617 | 0.01    |
| Total Tregs (CD4+CD25highCD127lowFoxP3+) | 0.4485 | 0.07 |
| Naive Tregs (CD45RA+CD28+ Tregs) | -0.0487 | 0.0001 |
| CM Tregs (CD45RA+CD28+ Tregs) | 0.6559 | 0.007 |
| EM Tregs (CD45RA+CD28+ Tregs) | 0.5567 | 0.02 |
| TD Tregs (CD45RA+CD28+ Tregs) | -0.5243 | 0.03 |
| CTLA4+ Tregs                | -0.0611 | 0.7     |
| PD1+ Tregs                  | 0.5765 | 0.02 |
| CTLA4+PD1+ Tregs            | -0.3429 | 0.1     |
| Mem CTLA4+PD1+ FoxP3+       | 0.0235 | 0.9     |
| CD39+ Tregs                 | 0.07506 | 0.7     |
| LAP(TGF-β1)+ Tregs          | -0.5085 | 0.04 |
| CD39+LAP(TGF-β1)+ Tregs     | -0.1927 | 0.4     |
| CXCR3+ Tregs                | -0.5901 | 0.01 |
| CCR5+ Tregs                 | 0.7334 | 0.001 |
| Integrin β7+ Tregs          | 0.6500 | 0.007 |
| CCR9+ Tregs                 | -0.5321 | 0.03 |
| Integrin β7+CCR9+ Tregs     | -0.5603 | 0.04 |
| Integrin β7+LAP(TGF-β1)+ Tregs | 0.5950 | 0.01 |
| CCR9+CCR9+ Tregs            | -0.3812 | 0.1 |
| CCR9+LAP(TGF-β1)+ Tregs     | 0.4183 | 0.1 |
| Th17 cells                  | -0.3765 | 0.15 |
| Th17/Treg ratio             | 0.3029 | 0.25 |
| CD31 FoxP3+                 | 0.5441 | 0.03 |
| CD31+FoxP3+                 | 0.6696 | 0.005 |
| Helios FoxP3+               | 0.6265 | 0.01 |
| Helios+FoxP3+               | 0.4059 | 0.12 |
| HLA-DR/CD38/FoxP3+          | 0.5578 | 0.02 |
| CNS1 demethylation          | -0.1655 | 0.5     |

p-values come from the comparison of clinical and immunological parameters with the duration of ART (years) by using the Spearman correlation coefficient test.

Significant differences (p < 0.05) are highlighted in Bold.
3.5. Early ART failed to normalize Tregs migration potential toward the gut

We previously demonstrated that Treg accumulation within GALT begins in acute HIV infection [28]. To assess the Treg capacity to migrate to inflammatory tissues and the gut, we analysed the expression of CXCR3 [53,54] and CCR6 [55] which mediate Treg recruitment to mucosal and inflammatory sites. HIV infection increased both CXCR3+ and CCR6+ Treg subsets, while early ART initiation was unable to normalize the CCR6+ Tregs levels (Fig. 4a, g, h). Furthermore, we also assessed the expression of Integrin-β7+, which directs Tregs migration from blood into the gut via the interaction with Mucosal vascular-Addressin Cell-Adhesin Molecule 1 [56-60] and CCR9, a chemokine receptor that binds to CCL25 and promotes Treg migration to the small intestine [60-62]. HIV infection was associated with an increase in Integrin-β7+ and CCR9+ Treg subsets, which were not restored following early ART initiation (Fig 4b, i, j). Notably, CD39+ and LAP(TGF-β1)+ Tregs were all increased during acute HIV infection compared to uninfected participants and were not restored following early ART initiation (Fig. 4c-f, k-n). However, a significant decline was observed in frequencies of Tregs expressing gut homing markers along with the longer duration of ART (Table 3). Significantly, the frequencies of CCR9+CD39+, CCR9+LAP(TGF-β1)+, Integrin-β7+CD39+, and Integrin-β7+LAP(TGF-β1)+ Tregs positively correlated with CD4 and CD8 immune activation, and negatively with CD4/CD8 ratio as an indicator of disease progression (Supplementary Fig. 5). A positive correlation was observed between VL and CCR9+LAP(TGF-β1)+ and Integrin-β7+LAP(TGF-β1)+ Tregs, while no correlation was detected with CCR9+CD39+ and Integrin-β7+CD39+ Tregs (Supplementary Fig. 5), suggesting the accumulation of CD39+ Tregs in the gut regardless of VL.

ECs and ICs represented similar levels of CXCR3+, Integrin β7+, CCR9+, Integrin β7+CD39+ and CCR9+CD39+ Tregs than uninfected individuals. Importantly, Integrin-β7+LAP(TGF-β1)+ Tregs and CCR9+LAP(TGF-β1)+ Tregs were significantly higher in ECs (Mann-Whitney p=0.03 and p=0.004, respectively) and ICs (Mann-Whitney p=0.005 and p=0.003, respectively) than uninfected individuals, suggesting the accumulation of pro-fibrotic Tregs even in these individuals (Fig 4). Moreover, lower frequencies of CCR6+ Tregs were observed in EC individuals compared to HIV uninfected controls.
Figure 3. Early ART initiation was unable to normalize Tregs subsets with known immunosuppressive functions. Gating strategies used to define (a) CTLA4+ and PD1+ Tregs, (b) Memory (CD45RA- CD4) CTLA4+PD1+FoxP3+ CD4 T-cells, (c) CD39+ and LAP(TGF-b1)+ Tregs. (d) Percentages of CTLA4+ Tregs within CD4 T-cells. (e) Percentages of PD1+ Tregs within CD4 T-cells. (f) Percentages of CTLA4+PD1+ Tregs within CD4 T-cells. (g) Percentages of Memory CTLA4+PD1FoxP3+ within CD4 T-cells. (h) Percentages of CD39+ Tregs within CD4 T-cells. (i) Percentages of LAP(TGF-b1)+ Tregs within CD4 T-cells. Differences among six study groups was determined by nonparametric Mann-Whitney rank test for unpaired variables, while the Wilcoxon rank tests were used for paired variables in the follow-up study. Sample size in Cross-sectional analysis: non-infected n=20, Acute n=26, Chronic ART- n=10, Chronic ART+ n=11, EC n=18, IC n=18; Sample size in longitudinal analysis: non-infected n=20, ART- n=10, ART+ n=10.
Figure 4. Impact of early ART initiation on Tregs migratory potential toward the gut. Gating strategies used to define (a) CXCR3+ and CCR6+ Tregs, (b) CCR9+ and Integrin-β7+ Tregs, (c) Integrin-β7+CD39+ Tregs, (d) Integrin-β7+LAP(TGF-β1)+ Tregs, (e) CCR9+CD39+ Tregs, (f) CCR9+LAP(TGF-β1)+ Tregs. (g) Percentages of CXCR3+ Tregs within CD4 T-cells. (h) Percentages of CCR6+ Tregs within CD4 T-cells. (i) Percentages of Integrin-β7+ Tregs within CD4 T-cells. (j) Percentages of CCR9+ Tregs within CD4 T-cells. (k) Percentages of Integrin-β7+CD39+ Tregs within CD4 T-cells. (l) Percentages of Integrin-β7+LAP(TGF-β1)+ Tregs within CD4 T-cells. (m) Percentages of CCR9+Tregs within CD4 T-cells. Statistical significance is indicated in the figures (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). Differences among six study groups was determined by nonparametric Mann-Whitney rank test for unpaired variables, while the Wilcoxon rank tests were used for paired variables in the follow-up study. Sample size in Cross-sectional analysis: non-infected n=20, Acute n=26, Chronic ART- n=10, Chronic ART+ n=11, EC n=18, IC n=18; Sample size in longitudinal analysis: non-infected n=20, ART- n=10, ART+ n=10.
Altogether, our results showed that, during HIV infection and despite early ART initiation, immunosuppressive CD39+ and LAP (TGF-β1)+ Tregs continued to migrate to the gut which, in turn, could contribute to disease progression and mucosal fibrosis.

3.6. Early ART initiation restored Th17/Treg ratio

Memory CCR6+ Th17 cells are highly permissive to HIV infection and are rapidly depleted following the infection, which results in the breakdown of gut mucosal integrity and microbial translocation [42,63,64]. Here, the frequency of Th17 cells was lower among both untreated and ART+ chronically infected individuals compared to uninfected controls (Mann-Whitney p=0.0093 and p=0.0099, respectively), while early ART was unable to affect their frequencies (Fig. 5a, b). Accordingly, the Th17/Treg ratio, a well-known marker of GALT integrity and immunological function, also decreased in untreated chronically HIV-infected individuals versus uninfected participants (Mann-Whitney p=0.0009 and p=0.0099, respectively), while early ART was unable to affect their frequencies (Fig. 5a, b). Accordingly, the Th17/Treg ratio, a well-known marker of GALT integrity and immunological function, also decreased in untreated chronically HIV-infected individuals versus uninfected controls (Mann-Whitney p=0.0093 and p=0.0099, respectively), while early ART was unable to affect their frequencies (Fig. 5a, b).

In this sense, a negative correlation was observed between the Th17/Treg ratio and the duration of the infection (Fig. 5d). Similarly, in ECs, a negative correlation between the frequencies of Th17 cells and the duration of the infection was also detected (Fig. 5e). Our data demonstrated that early ART initiation but not the duration of ART (Fig 5c; Table 3) normalized the Th17/Treg ratio.

3.7. Early ART failed to decrease the expansion of peripheral pTregs

As Tregs can either be differentiated in the thymus (tTregs) or in the peripheral tissues (pTregs) during inflammation [2], to assess their origin we evaluated the expression of CD31, a marker of recently thymic migrated CD4 T-cells[65], and Helios, a well-known specific marker of thymic Tregs [66,67] (Fig. 6a). We observed an increase in the frequencies of CD31+FoxP3+ and Helios+FoxP3+ CD4 T-cells overtime during HIV infection (cross-sectional acute versus uninfected Mann-Whitney p=0.03 and p=0.002, respectively), suggesting increases in pTreg differentiation, whereas Helios+FoxP3+ CD4 T-cells was not normalized by early ART initiation (Fig. 6c, e). We also observed an increasing trend in the frequencies of thymic Helios+FoxP3+ and CD31+FoxP3+ CD4 T-cells following HIV infection, while only Helios+FoxP3+ were normalized after early ART (Fig. 6d, e). Additionally, the frequencies of CD31+FoxP3+ and Helios+FoxP3+ pTregs were correlated positively with VL and negatively with CD4/CD8 ratio, suggesting the expansion of pTregs along with disease progression (Supplementary Fig. 6). Interestingly, ECs and ICs had significantly lower frequencies of both tTregs and pTregs compared to untreated HIV-infected individuals and uninfected controls (Fig. 6). In line with the increased extrathymic generation of Tregs, which are
mainly induced during inflammation, we observed increased immune activation of FoxP3+ CD4 T-cells (HLA-DR’CD38’) in untreated HIV-infected individuals that was not reduced following early ART initiation (Fig. 6a, g). Moreover, we observed that long-term ART was associated with a decrease in pTregs (Helios’ FoxP3+) and activated Tregs (HLA-DR’CD38’FoxP3’), while no correlation was observed on thymic Tregs (Helios’ FoxP3+) (Table 3). ECs and ICs had lower levels of Treg immune activation than other HIV-infected individuals (Fig. 6g). Altogether, early ART initiation failed to decrease pTreg expansion and Treg immune activation.
3.8. Early ART initiation normalized the CpG demethylation status of CNS1 region of the foxp3 gene

Methylation of the foxp3 gene has an essential role in transcription of the gene, which further translates to cell phenotype and activity[68]. We thus evaluated the methylation status of the six regulatory regions of the foxp3 gene in FACS-sorted CD4+FoxP3+ cells (Supplementary Fig. 1). CNS0, CNS1, CNS3, enhancer, and proximal promoter were highly demethylated among study groups, and no significant differences were observed in sorted cells (Table 4). In contrast, and in line with the observed expansion of pTregs overtime of the infection (Fig. 6), increases in CNS1 demethylation status were observed in untreated chronically HIV-infected individuals versus uninfected individuals (Mann-Whitney p=0.007) while early ART initiation normalized the levels of CNS1 demethylation (Fig. 7a). Additionally, no correlation was observed between the duration of ART and CNS1 demethylation (Table 3).

4. Discussion

Early ART initiation as close as possible to the estimated time of HIV exposure is highly recommended in clinical practice due to its proven benefits in facilitating CD4 T-cell count recovery, decreasing immune activation, and reducing secondary HIV transmission [43,46]. The GALT represents one of the major sites of SIV/HIV replication, CD4 depletion, and immune dysfunction [2,34,42-45]. Our team and others have previously shown that GALT fibrosis and microbial translocation start early following HIV/SIV infections along with increased frequencies of immunosuppressive Tregs and TGF-b1 production [28,30,41,69-71]. Herein, we assessed the impact of early ART initiation and duration of ART on the dynamics of Treg immunomodulatory subsets.

Similar to other studies [2,10,28], we observed increased frequencies of total CD4^CD25^{high}CD127^{low}FoxP3^ Tregs in untreated HIV-infected individuals, which were normalized by early ART, while ECs showed lower Tregs frequencies than HIV-progressors and similar to uninfected individuals [18,72-75]. A distinctive differentiation

Table 4

Demethylation levels of CpG sites at regulatory regions of foxp3 locus.

| Region        | HIV-non infected (n= 11) | Acute (n=26) | Chronic ART-(n= 6) | Chronic ART+(n= 77) | EC (n= 10) | IC (n= 10) | p-values |
|---------------|--------------------------|--------------|--------------------|---------------------|-----------|-----------|----------|
| Enhancer      | Median [IQR]             | 99 [98-99]   | 99 [98-100]        | 99 [97.5-99.25]     | 99.5 [98-98.75] | 99.5 [98-99.25] | 0.76     |
| Proximal promoter Median [IQR] | 97 [93-100] | 97 [85-100] | 98 [96-99.25] | 99.5 [97-100] | 98 [96.5-100] | 95.5-99.25 | 0.85     |
| CNS0          | Median [IQR]             | 85 [84-88]   | 82 [77-89]         | 86 [82-90.25]       | 89.5 [87.5-97.75] | 80.5-84.75 | 0.05     |
| CNS2          | Median [IQR]             | 82 [75-96]   | 78 [53.75-99]      | 94 [78.25-98.25]    | 90.5 [81.25-93.5] | 91-93.5  | 0.86     |
| CNS3          | Median [IQR]             | 96 [95-99]   | 97 [92.5-99]       | 98 [97-100]         | 96.5 [95-99.25] | 94.75-98.25 | 0.56     |

Percentage of CpG demethylation was determined by bisulfite conversion and next generation sequencing of genomic DNA from CD4^FoxP3^ T cells on six regulatory regions: enhancer, proximal promoter, CNS0, CNS1, CNS2, and CNS3. Results are shown as median and interquartile range (IQR) of percentage of demethylation, and on average 30000 mapped reads were analyzed for each sample.

p-values come from comparing the six groups using the Kruskal-Wallis test.

Figure 7. Impact of early ART on CpG sites demethylation of CNS1 region in the foxp3 gene. (a) Percentage of CNS1 demethylation within the foxp3 gene. Statistical significance is indicated in the figures (*, P < 0.05). Differences among six study groups was determined by nonparametric Mann-Whitney rank test for unpaired variables, while the Wilcoxon rank tests were used for paired variables in the follow-up study. Sample size in Cross-sectional analysis: non-infected n=11, Acute n=26, Chronic ART- n=6, Chronic ART+ n=77, EC n=10, IC n=10; Sample size in longitudinal analysis: non-infected n=11, ART- n=10, ART+ n=10.
pattern of Tregs was observed in acute HIV infection, which was characterized by higher proportions of naïve Tregs along with low frequencies of CM and EM Tregs, while in longitudinal analysis early ART initiation didn’t affect these subsets. Increase naïve Tregs during untreated infection is likely to be related to a higher thymic output along with the observed increase in Helios+/Foxp3+ CD4 T-cells over time in our study. This increase in naïve Tregs might also be related to a slow differentiation rate of these cells into CM Tregs during HIV infection [76]. In addition, the low frequencies of CM and EM Tregs in peripheral blood could also indicate higher retention of these cells in lymphoid organs [77,78] or preferential HIV-induced apoptosis of CM Tregs [76].

Early ART had failed to decrease the expression of CTLA4 and PD1 by Tregs which, in turn, might contribute to an increase in Treg-mediated inhibition of effector T-cell proliferation, HIV-specific responses, and cytokine production [1,14,21,22]. Enhanced PD1/PD1L interaction could promote Tregs’ development and suppressive functions by stabilizing and maintaining Foxp3 during HIV infection [79-82]. Our study also revealed an increase in memory CTLA4+PD1+ Foxp3+ T-cells during acute HIV infection. This subset has been recently shown as viral reservoirs in SIV infection during suppressive ART [51], suggesting a potential contribution of Tregs in viral persistence despite early ART. Tregs in EC and IC groups expressed similar CTLA4 levels than uninfected individuals, which could be related to the maintenance of effector cell functions and further better viral control in these individuals compared to HIV progressors.

Increased CD39 expression by Tregs and their production of immunosuppressive adenosine in chronic HIV infection under ART are involved in HIV disease progression [16,26,27,83]. Here, we observed that levels of CD39+ Tregs remained higher in blood of ART-treated individuals than uninfected controls. Neither timing of ART initiation, nor duration of ART, were capable of normalizing the frequencies of CD39+ Tregs which may contribute to chronic immune dysfunction despite ART, as we previously reported [25,27]. Furthermore, the upregulation of downstream genes of the TGF-β1 pathway occurs as early as one day post-SIV infection of rhesus macaques [84]. We recently showed that early ART initiation at four days post-SIV infection in rhesus macaques is unable to decrease TGF-β1 [28]. Accordingly, here we observed an increase in LAP(TGF-β1)+ Tregs during HIV infection that was not restored following ART. Notably, there is a functional positive feedback between CD39 and TGF-β1. CD39 enzymatic activity and the excessive generation of adenosine promote TGF-β1 production and tissue remodelling and fibrosis [85-87], while the TGF-β1 signalling induces CD39 expression and activity [88-91]. The adenosine pathway could also promote the generation of FoxP3+ Treg cells [92,93] via the stimulation of TGF-β1 production [31,32]. Importantly, TGF-β1 regulates Treg trafficking to the gut [94,95], and CD39+ Tregs maintain their suppressive capacity and exhibit high Foxp3 expression and stability in inflammatory conditions [96].

We found that HIV infection is associated with an early increase in the expression of homing markers CXCR3, CCR6, Integrin β7, and CCR9 by Tregs, which were not normalized by early ART, while negative correlations were observed between their frequencies and duration of ART. Our results are in line with other reports showing increased CXCR3+ and Integrin β7+ Tregs [98,99] frequencies in HIV-infected individuals and a decrease in small intestinal mucosal CCR6+ Treg following ART [100]. We also found that expression of the gut homing markers by CD39+ Tregs and LAP(TGF-β1)+ Tregs were increased during HIV infection and occurred even in ECs and ICs, but not restored by early ART. This suggests a potential key role of CD39/TGF-β1 interplay in gut mucosal fibrosis and dysfunction, even in the absence of detectable VL.

Altered Th17/Treg balance in favour of Tregs is a main cause of gut mucosal immune dysfunction, which facilitates microbial translocalization from gut to peripheral blood, promoting generalized inflammation [47,101-103]. In line with previous reports [28,104,105], we found a decrease in both Th17 cell frequencies and Th17/Treg ratio during HIV infection, while timing of ART initiation but not duration of ART restored Th17/Treg ratio. We also found a lower Th17/Treg ratio in EC versus other HIV-infected individuals or uninfected controls, contrasting with previous reports [74,102,106]. Individuals in the EC group were significantly older than other HIV-infected individuals, which could explain the lower Th17/Treg ratio in these individuals since Th17/Treg balance is disturbed during aging [107]. Besides, we found a negative correlation between the Th17/Treg ratio and the duration of the infection in ECs, suggesting long-term suboptimal immune function and impaired gut barrier functions despite their undetectable viremia [108,109].

To better evaluate the origin of Treg expansion during untreated HIV infection, we assessed the expression of CD31 as a marker of recently thymus emigrant Tregs and Helios, a specific marker of thymic Tregs [65-67]. We observed an increase in CD31+ and Helios+ Foxp3+ CD4 T-cells in untreated HIV infection, while early ART initiation failed to reduce the frequencies of Helios+ Foxp3+ CD4 T-cells along with the observed increase in the total Treg pool. Additionally, we demonstrated an increase in Helios+Foxp3+ CD4 T-cells over time in untreated individuals, indicating increased thymic output of Tregs in these individuals, which was normalized by early ART. Notably, compared to Helios- Tregs, Helios+ Tregs are more stable and proliferative in vivo and produce high levels of TGF-β1 [110,111]. Significantly, in line with previous reports [23,112], we found that HIV infection was associated with an increase in HLA-DR+CD38+ Foxp3+ CD4 T-cells, which was not normalized following early ART, and declined along with ART duration. The maintenance of activated Foxp3+ CD4 T-cells after early ART is important since this population shows greater suppressive function [113].

For the first time, we assessed the methylation status of the six regulatory regions of foxp3 locus, i.e., enhancer, proximal promoter, and exons 3-5, to assess the epigenetic regulation of Tregs in HIV infection. We detected significant increases over time only in CNS1 demethylation in untreated HIV-infected individuals that were normalized following early ART initiation. The CNS1 region includes binding sites for several transcription factors, including Smads, nuclear factor of activated T-cells (NFAT), activator protein 1 (AP-1), and retinoic acid receptor (RAR) [7]. Significantly, TGF-β1 induces the binding of Smad2/3 to CNS1 in the foxp3 locus, which is crucial for Foxp3 induction and differentiation of pTregs [114]. CNS1 demethylation is in line with our finding with the increase in LAP(TGF-β1)+ Tregs and expansion of Helios+ Foxp3+ Tregs in untreated HIV infection. Notably, we did not observe any differences in CNS2 demethylation, a well-known regulatory region that contributes to continuous expression of Foxp3 in tTregs and their stability [115-117], which was in line with frequencies of Helios+ Foxp3+ Tregs, and with previous reports on rarely CNS2 demethylation in conventional T-cells or TGF-β-induced iTregs generated in vitro [116]. We observed higher levels of LAP(TGF-β1)+ Tregs in ECs than uninfected individuals, along with no differences in CNS1 demethylation between these two study groups. Our results suggest that other possible mechanisms, in addition to the effect of LAP(TGF-β1) on CNS1 demethylation might be involved in differential Treg homeostasis in ECs [73,74,112]. As such, we previously reported distinct tryptophan catabolism in ECs which is known to be involved in the generation of pTregs in HIV infection [47]. Furthermore, the induction of pTregs is impaired with age, while tTregs are increased with age [118]. Accordingly, the older age in ECs could also explain, partially, the lack of significant difference in CNS1 demethylation in ECs versus uninfected individuals.

The findings of this study must be considered in light of some limitations. We acknowledge that confounders such as sex, age, duration of infection and the timing of ART initiation, might impact our observations. Males and persons of older age are known to have higher Tregs frequencies compared to females [119-121] and younger individuals [122-124]. Additionally, sex and age-related differences exist.
in the expression of immune checkpoints PD1 and CTLA4 [125,126], and, TGF-β1 [127–130]. In our study, we mainly included male individuals since the majority of participants in the Montreal primary infection (acute) cohort are male. Furthermore, as previously indicated, the methylation status of the foxp3 gene can be done adequately only in males [49]. The higher proportion of females in the EC and IC groups was due to the availability of these rare specimens and a higher number of women in these study cohorts, which, in turn, might impact some of our observations. The significant older age in both EC and chronic ART+ groups in the cross-sectional study, might also affect our results. As such, the discordances in CTLA4, PD1, CD31 or CCR6 expression by Tregs in ART+ individuals in cross-sectional versus longitudinal studies, might be explained by the significantly older age of ART+ individuals in cross-sectional specimens along with their significantly longer duration of infection. We also recognize that the small sample size available for our study is a limitation and would benefit from replication. However, our findings are in keeping with our previous results and have high biological plausibility [47,69,131–134]. Moreover, due to the limited availability of the specimens, we were not able to perform in vitro Treg functional assays. Finally, although we used well-known markers of T-cell migration to the gut, all assessments were done in peripheral blood as an indirect indicator of Treg migration into the GALT. Further studies to evaluate the dynamics of Tregs in gut mucosal tissue are needed to confirm our observations.

In summary, we showed that even though early ART initiation clearly improved CD4 recovery and T-cell immune activation and exhaustion, the frequencies of immunosuppressive and pro-fibrogenic Tregs and their potential migration toward the gut overtime were not affected by early ART. Our results suggest that immunotherapies which impact the CD39/TGF-β1 pathway or reduce Treg homing to gut could be tested in clinical trials as adjuncts to ART to prevent gut mucosal fibrosis.

Contributors

MAJ designed the study; AY, TS, OF performed the experiments. JPR, CHT, CT, CTC provided access to specimens and clinical data; AY, TS, OF, MD, CTC, MAJ analysed, discussed, and interpreted results throughout the study. AY and MAJ wrote the paper. All authors contributed to the refinement of the study and reviewed and approved the final version of manuscript. AY, TS, MD and MAJ have verified the underlying data.

Data sharing

Data from this manuscript is available from the corresponding author upon reasonable request.

Declaration of Competing Interest

We have no competing of interest to declare.

Acknowledgments

First and foremost, the authors thank all study participants for their time and significant dedication to this study. Subjects in the early phase of infection were screened, recruited, and followed up at the following Montreal-based clinics and we thank for their collaboration: Actuel Medical Clinic, Quartier Latin Medical Clinic, UHRESS CHUM Hôtel-Dieu and Notre-Dame; and MUHC Chest Institute. We also thank M. Mario Legault, for administrative support, Ms. Angie Massicotte, for her assistance and coordination; Ms. Louise Gilbert for the MUHC biobanking support; and Ms. Stephanie Matte from the Canadian HIV-1 Slow Progressor cohort. This study was funded by the Canadian Institutes of Health Research (CIHR, grant MOP 142294) and in part by the AIDS and Infectious Diseases Network of the Réseau SIDA et maladies infectieuses du Fonds de recherche du Québec-Santé (FRQ-S) to MAJ. AY is supported by an FRQ-S doctoral scholarship. JPR holds the McGill University Louis Lowenstein Chair in Hematology and Oncology. CT holds the Pfizer Chair in Clinical and Translational Research on HIV. MD and CTC hold FRQ-S Junior 2 Clinician-researcher career awards. MAJ holds the tier 2 CIHR Canada Research Chair in Immuno-Virology.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.ebiom.2021.103570.

References

[1] Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T Cells and Human Disease. Annual Review of Immunology 2020;38(1):541–66.
[2] Jenabian MA, Ancuta F, Gilmore N, Routy JP. Regulatory T cells in HIV infection: can immunotherapy regulate the regulator? Clin Dev Immunol 2012;2012:908314.
[3] Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012;30:531–64.
[4] Mohr A, Atif M, Balderas R, Gorochov G, Miyara M. The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases. Clin Exp Immunol 2019;197(1):24–35.
[5] Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the foxp3 gene in regulatory T-cell fate. Nature 2010;463(7282):808–12.
[6] Mohr A, Malhotra R, Mayer G, Gorochov G, Miyara M. Human FOXP3+ regulatory T cell heterogeneity. Clin Transl Immunology 2018;7(1):e1005.
[7] Sekiya T, Nakatukasa H, Lu Q, Yoshihama A. Roles of transcription factors and epigenetic modifications in differentiation and maintenance of regulatory T cells. Microbes Infect 2016;18(6):378–86.
[8] Feng Y, van der Veeken J, Shugay M, Putintseva EV, Osmanbegoylu HR, Diksy S, et al. A mechanism for expansion of regulatory T-cell repertoire and its role in self-tolerance. Nature 2015;528(7580):132–6.
[9] Chevalier MF, Didier C, Pettitjean G, Karmokichine M, Girard PM, Barre-Sinoussi F, et al. Phenotype alterations in regulatory T-cell subsets in primary HIV infection and identification of T1-like cells as the main interleukin-10-producing CD4+ T cells. J Infect Dis 2015;211(5):769–79.
[10] Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. Blood 2013;121(1):29–37.
[11] Kleinman AJ, Sivanandham R, Pandrea I, Choungu A, Apetrei C. Regulatory T Cells As Potential Targets for HIV Cure Research. Front Immunol 2018;9:734.
[12] Abdel-Hameed EA, Ji H, Sherman KE, Sha ta MT. Epigenetic modification of FOXP3 in patients with chronic HIV infection. J Acquir Immune Defic Syndr 2014;65(1):19–26.
[13] Pion M, Jaramillo-Ruiz D, Martinez A, Munoz-Fernandez MA, Correa-Rocha R. HIV infection of regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene. AIDS 2013;27(11):29–35.
[14] Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. Science 2011;332(6029):600–3.
[15] Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Feihervari Z, et al. CTLA-4 control over Foxp3 regulatory T cell function. Science 2008;322(5909):271–5.
[16] Schuler Zur Wiesch J, Thomassen A, Hartjen P, Toth I, Lehmann C, Meyer-Okel D, et al. Comprehensive analysis of frequency and phenotype of regulatory T cells in HIV infection: CD39 expression of Foxp3+ regulatory T cells correlates with progressive disease. J Virol 2011;85(3):1287–97.
[17] Vallejo A, Abad-Fernandez M, Moreno S, Moreno A, Perez-Elias MJ, Dronda F, et al. High levels of CD4+ CTLA-4+ Treg cells and CCR5 density in HIV-1-infected patients with visceral leishmaniasis. Eur J Clin Microbiol Infect Dis 2015;34(2):267–75.
[18] Rueda CM, Velilla PA, Choungu A, Ru eges MT. Incomplete normalization of regulatory T-cell frequency in the gut mucosa of Colombian HIV-infected patients receiving long-term antiretroviral treatment. PLoS One 2013;8(8): e71092.
[19] Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. ImmunoL Reviews 2010;236(1):219–42.
[20] Rodriguez-Perea AL, Arcia ED, Rueda CM, Velilla PA. Phenotypical characterization of regulatory T cells in humans and rodents. Clin Exp Immunol 2016;185(3):281–91.
[21] Asano T, Kishi Y, Meguri Y, Yoshio kka T, Iwamoto M, Maeda Y, et al. PD-1 Signal ing Has a Critical Role in Maintaining Regulatory T Cell Homeostasis; Implication for Treg Depletion Therapy By PD-1 Blockade. Blood 2015;126(23):3488.
[22] Zhang B, Chikuma S, Hori S, Fagarasan S, Honjo T. Nonoverlapping roles of PD-1 and Foxp3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model. Proc Natl Acad Sci U S A 2016;113(30):8400–5.
Xiao J, Zhang L, Dong Y, Liu X, Peng L, Yang Y, et al. PD-1 Upregulation is Associated with Exhaustion of Regulatory T Cells and Reflects Immune Activation in HIV–1-Infected Individuals. AIDS Res Hum Retroviruses 2019;35(5):444–52.

Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD19 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204(6):1257–65.

Jenabian MA, Seddiki N, Yatim A, Carriere M, Hulin A, Younas M, et al. Regulatory T cells and Th17 cell expansion in HIV infection. PLoS Pathog 2013;9(4):e1003319.

Presicce P, Orsborn K, King E, Pratt J, Fichtenbaum CJ, Chougnet CA. Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy. PLoS One 2011;6(12):e28118.

Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kok A, et al. CD39/adenosine pathway in HIV infection is involved in AIDS progression. PLoS Pathog 2011;7(7):e1002110.

Yero A, Farnes O, Rabezhanarhy H, Racine G, Estajour J, Jenabian MA. Differential Dynamics of Regulatory T-Cell and Th17 Cell Balance in Mesenteric Lymph Nodes and Blood following Early Antiretroviral Initiation during Acute Simian Immunodeficiency Virus Infection. J Virol 2011;85(19):9319-31.

Estes JD, Wietgrefe S, Schacker T, Southern P, Beilman G, Reilly C, et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor alpha-1 positive regulatory T cells and begins in early infection. J Infect Dis 2007;195(4):559–61.

Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid cancer tissue. Cancer Res 2009;69(3):599–608.

Huen J, Polansky JK, Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol 2009;9(2):83–93.

McGarry CS, Deleage C, Brown C, Mayer G, LCCONOP, GP, Patagia S, et al. CTLA-4(+) Memory CD4(+) T Cells Critically Contribute to Viral Persistence in Anti-retroviral Therapy-Suppressed, SV-Infected Rhesus Macaques. Immunity 2013;39(4):776–88.

Kim KK, Sheppard D, Chapman HA. TGF-β1 Signaling and Tissue Fibrosis. Cold Spring Harb Perspect Biol 2018;10(4):a022933.

Hasegawa H, Inoue A, Kohno M, Lee J, Miyazaki T, Yoshi E, et al. Therapeutic effect of CCRX3-expressing T cells on viral load, lung and intestinal damage in a murine acute GHVMD model. Gene Therapy 2008;15(3):171–82.

Chow Z, Banerjee A, Hickey MJ. Controlling the fire—tissue-specific mechanisms of effector regulatory T-cell homing. Immunol Cell Biol 2015;93(4):355–63.

Yamazaki T, Yang X, Liu Y, Kong X, Pappu P, et al. CRISPR regulates the migration of inflammatory and regulatory T cells. J Immunol 2008;181(12):8391–401.

Berlin C, Berg EL, Birskin MJ, Andrew DP, Klipshov PJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MADCAM-1. Cell 1993;74(4):185–95.

Wagner N, Löhler J, Kunkel EJ, Ley K, Leung E, Krisanassen C, et al. Critical role of beta(7) integrin in formation of the gut-associated lymphoid tissue. Nature 1996;382(6589):366–70.

Sun H, Kuk W, Rivera-Nieves J, Lopez-Ramirez M, Eckmann L, Gins MH, beta7 Integrin Inhibition Can Increase Intestinal Inflammation by Impairing Homing of CD25(high)/FoxP3(+) Regulatory T Cells. Cell Mol Gastroenterol Hepatol 2017;4(5):420–37.

Zhang HL, Zheng YJ, Pan YD, Xie C, Sun H, Zhang YH, et al. Regulatory T-cell deletion in the gut caused by inhibiting beta7 deficiency exacerbates DSS colitis by evolving aberrant innate immunity. Mucosal Immunol 2016;9(5):391–400.

Pabst M, Trickfoot K, Cafeau J, Egermann L. Regulatory T cells in the intestinal immune system. Immunity 2013;35(5):139–43.

Uehara S, Crimberg A, Farber JM, Love PE. A Role for CR9 in T Lymphocyte Development and Migration. The Journal of Immunology 2002;168(6):2811–9.

Hoeppli RE, MacDonald KN, Leclat P, Fung WCW, Johansson M, Sani M, et al. Controlling the homing capacity of human Tregs for directed migration to sites of Th1–induction or infection. Am J Transplant 2019;19(1):62–76.

Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said AE, Fonseca S, et al. Peripheral blood CCR6+ and CCR4+CCR6+ CD4+ T cells are highly permissiveto HIV-1 infection. J Immunol 2010;184(3):1604–16.

Monteiro P, Gosselin A, Wacleche VS, El-Far M, Said AE, Kared H, et al. Memory CCR4+CCR6+ T-cell compartments are preferential targets for productive HIV type 1 infection regardless of their expression of integrin beta7. J Immunol 2011;186(8):4618–30.

Douaisi M, Resop RS, Nagawa S, Court J, Jameson BD, Blom M, et al. CD31, a Valuable Marker to Identify Early and Late Stages of T Cell Differentiation in the Human Thymus. J Immunol 2017;198(6):2310–9.

Takatori H, Kawashima H, Matsuoka A, Meguro T, Tanaka S, Iwamoto T, et al. Helios Enhances Treg Cell Function in Cooperation With Foxp3. Arthritis Rheum 2015;67(6):1491–502.

Thornton AM, Korn J, Baelum KG, Wohlfert EA, Murray PE, Belkaid Y, et al. Interfering with regulatory T cells in the intestinal immune system. Cell Death Differ 2011;18(4):714–25.

Nilsson J, Boasso A, Velilla PA, Zhang X, Vaccarelli G, et al. Helios Deficiency Blunts T-Cell Homeostasis and Function in Cancer. Cell 2014;159(6):1241–52.

Hoeppli RE, MacDonald KN, Leclat P, Fung WCW, Johansson M, Sani M, et al. Controlling the homing capacity of human Tregs for directed migration to sites of Th1–induction or infection. Am J Transplant 2019;19(1):62–76.

Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said AE, Fonseca S, et al. Peripheral blood CCR6+ and CCR4+CCR6+ CD4+ T cells are highly permissiveto HIV-1 infection. J Immunol 2010;184(3):1604–16.

Monteiro P, Gosselin A, Wacleche VS, El-Far M, Said AE, Kared H, et al. Memory CCR4+CCR6+ T-cell compartments are preferential targets for productive HIV type 1 infection regardless of their expression of integrin beta7. J Immunol 2011;186(8):4618–30.

Douaisi M, Resop RS, Nagawa S, Court J, Jameson BD, Blom M, et al. CD31, a Valuable Marker to Identify Early and Late Stages of T Cell Differentiation in the Human Thymus. J Immunol 2017;198(6):2310–9.

Takatori H, Kawashima H, Matsuoka A, Meguro T, Tanaka S, Iwamoto T, et al. Helios Enhances Treg Cell Function in Cooperation With Foxp3. Arthritis Rheum 2015;67(6):1491–502.

Thornton AM, Korn J, Baelum KG, Wohlfert EA, Murray PE, Belkaid Y, et al. Interfering with regulatory T cells in the intestinal immune system. Cell Death Differ 2011;18(4):714–25.

Nilsson J, Boasso A, Velilla PA, Zhang X, Vaccarelli G, et al. Helios Deficiency Blunts T-Cell Homeostasis and Function in Cancer. Cell 2014;159(6):1241–52.
Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, et al. Critical loss of the
Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, et al. Extracellular adenosine contributes to penile fibrosis, a dangerous feature of prostatitis, via A2B adenosine receptor signaling. The FASEB J 2010;24(3):740–9.

Luo F, Le N-B, Mills T, Chen N-Y, Karmouty-Quintana H, Molina JG, et al. Extracellular adenosine levels are associated with the progression and exacerbation of pulmonary fibrosis. The FASEB J 2016;30(2):874–80.

Kunzli BM, Nuhn P, Enyoji K, Banya Y, Smith RN, Csizmadia E, et al. Disordered Pancreatic Inflammatory Responses and Reduction of Fibrosis in CD39-Null Mice. Gastroenterology 2008;134(1):292–305.

Franklin WT, Westrop CA, Cotter-James NC, Maitland PR, Machado CC, et al. TGF-β signaling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis. J Autoimmun 2011;36(3):194–9.

Ye Z-J, Zhou Q, Zhang J-C, Li X, Wu C, Qin S-M, et al. CD39+Regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respiratory Research 2011;12(1):77.

Regasero FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold SP, et al. Regulation of systemic immune activation. J Immunol 2013;191(5):2164–9.

Chen X, Oppenheim J. Resolving the identity myth: key markers of functional CD4+Foxp3+ regulatory T cells. Int Immunol 2011;23(10):1489–96.

Izukoa-Koga M, Nakatsukasa H, Ito M, Akamana T, Lu Q, Yoshimura A. Induction and maintenance of regulatory T-cell function by transcription factors and epigenetic modifications. J Autoimmun 2017;83:113–21.

Li X, Xiang Y, LeBlanc M, Benner C, Zheng Y. Function of a Foxp3 cis-element in protecting regulatory T cell identity. Cell 2014;158(4):734–46.

Floos S, Freyer J, Janzer G, Selk S, Polak A. Epigenetic control of the Foxp3 locus in regulatory T cells. PLoS Biol 2007;5(2):e38.

Rubtsov VP, Niec RE, Josewicz S, Li D, Jarvis M, et al. Stability of the regulatory T-cell lineage in vivo. Science 2010;329(599):1677–71.

Jagger A, Shimjojima Y, Goronyj JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology 2014;60(2):130–7.

Elderman M, van Beek A, Brandsma E, de Haan B, Savelkoul H, de Vos P, et al. Sex impacts Th1 cells, Tregs, and DCs in both intestinal and systemic immunity in a mouse strain and location-dependent manner. Biology of Sex Differences 2016;7(1):21.

Lin P-Y, Wu S, Wierman M, Tekmal R, Pierce A, Daniel B, et al. Sex-related differences in regulatory T-cell function are estrogen and B7-H1 dependent (143.53). The Journal of Immunology 2010;184(1 Supplement):143.53–53.

Asfahn G, Alafz N, Qureshi S. CD4+CD25(high) regulatory T cells in healthy males and females mediate gender difference in the prevalence of autoimmune diseases. Aging Cell 2014;13(3):441–8.

Darrigues J, van Meerwijk JPM, Romagnoli P. Age-Dependent Changes in Regulatory T Lymphocyte Development and Function: A Mini-Review. Gerontology 2018;64(1):28–35.

Gregg R, Smith CM, Clark DJ, Funnion D, Khan N, Chakraverty R, et al. The number of human peripheral blood CD4+CD25(high) regulatory T cells increases with age in the mouse strain and location-dependent manner. Biology of Sex Differences 2020;11(1):24.

Reitsema RD, Hid Cadena R, Nijhof SH, Abdulahad WH, Huitema MG, Paap D, et al. Effect of age and sex on immune checkpoint expression and kinetics in human T cells. Immunology & Ageing 2020;17(1):32.

Kim SV, Hwang WJ, Kwon J, Na KY, Park S, et al. Sex differences in regulatory T cells are associated with gender on immunotherapy outcomes. Biology of sex differences 2020;11(1):24.

Frydecka D, Misiak B, Pawlak-Adamska E, Karabon L, Tomkiewicz A, Sedlacek P, et al. Sex differences in TGF-B1 signaling with respect to age of onset and cognitively functioning in schizophrenia. Neuropsychiatr Dis Treat 2015;11:575–84.

Kriegstein K, Miyazono K, ten Dijke P, Unsicker K. TGF-β1 and TGF-β1 modulation of Smad3 signaling with respect to age of onset and cognitive functioning in schizophrenia. Neuropsychiatr Dis Treat 2015;11:575–84.

Klein SL, Morgan R. The impact of age and sex on lymphoid organ development and maintenance of regulatory T cells. Science Immunology 2018;3(150):eaan5243.

Reitsema RD, Hid Cadena R, Nijhof SH, Abdulahad WH, Huitema MG, Paap D, et al. Effect of age and sex on immune checkpoint expression and kinetics in human T cells. Immunology & Ageing 2020;17(1):32.

Kim SL, Morgan R. The impact of age and sex on lymphoid organ development and maintenance of regulatory T cells. Science Immunology 2018;3(150):eaan5243.